Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A. Dynorphins are a class of opioid peptides produced primarily in the central nervous system, where they play a pivotal role in modulating nociception, stress response, and neuroendocrine function (Chavkin & Goldstein, 1981, Proc Natl Acad Sci USA). The full-length dynorphin A consists of 17 amino acids, while the (2-17) fragment represents a truncated, bioactive sequence that retains significant physiological activity. The amide modification at the C-terminus enhances peptide stability and receptor affinity, making it a valuable tool for neuropharmacological research.

Dynorphin peptides exert their effects primarily through the kappa-opioid receptor (KOR), a G-protein coupled receptor (GPCR) distributed throughout the brain and spinal cord (Simonin et al., 1998, J Biol Chem). Activation of KOR by dynorphin (2-17) modulates neurotransmitter release, inhibits neuronal excitability, and influences pain perception, mood, and addiction pathways. The porcine sequence is highly homologous to the human peptide, enabling translational research applications.

[Related: 2'-3'-cyclic GMP-AMP] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has emerged as a critical research tool for elucidating the physiological and pathological roles of the dynorphin/KOR system. Its clinical value lies in its ability to model endogenous opioid activity, providing insights into pain modulation, stress adaptation, and neuropsychiatric disorders.

1. **Pain Modulation:** Dynorphin (2-17) is a potent modulator of nociceptive pathways. It has been shown to produce both analgesic and pronociceptive effects, depending on the site and context of administration (Vanderah et al., 1996, J Pharmacol Exp Ther). This duality is crucial for understanding chronic pain mechanisms and developing novel analgesics with reduced abuse potential.

[Related: GSK-3α and GSK-3β inhibitor] 2. **Neuropsychiatric Disorders:** Dysregulation of the dynorphin/KOR system has been implicated in depression, anxiety, and addiction. Dynorphin (2-17) serves as a model compound to study the neurobiological basis of these conditions and to screen potential therapeutic agents targeting KOR (Carlezon et al., 2009, Pharmacol Rev).

3. **Neuroprotection and Neurotoxicity:** Research indicates that dynorphin peptides may exert neuroprotective or neurotoxic effects depending on concentration and receptor context. Dynorphin (2-17) is used to investigate these mechanisms in models of neurodegenerative diseases and traumatic brain injury (Hauser et al., 1999, Brain Res).

[Related: Z-VAD-FMK] 4. **Endocrine Regulation:** The peptide also influences hypothalamic-pituitary-adrenal (HPA) axis activity, impacting stress hormone release and homeostasis (Nikolarakis et al., 1986, J Neurochem).

Key Challenges and Pain Points Addressed
Current opioid-based therapies for pain and mood disorders are limited by significant side effects, including tolerance, dependence, and respiratory depression. Traditional mu-opioid receptor (MOR) agonists, such as morphine, are effective analgesics but carry a high risk of abuse and overdose (Volkow & McLellan, 2016, N Engl J Med).

Dynorphin (2-17), by selectively targeting KOR, offers a distinct pharmacological profile. KOR agonists are associated with lower abuse potential and reduced respiratory depression compared to MOR agonists. However, KOR activation can also produce dysphoria and psychotomimetic effects, complicating therapeutic development (Wee & Koob, 2010, Pharmacol Ther).

The use of dynorphin (2-17) in preclinical research addresses several pain points:
- **Mechanistic Dissection:** Enables detailed study of KOR-mediated signaling pathways, facilitating the design of selective modulators with improved safety profiles.
- **Modeling Endogenous Opioid Function:** Provides a physiologically relevant tool for investigating endogenous opioid regulation in health and disease.
- **Screening Novel Therapeutics:** Serves as a reference compound for evaluating the efficacy and safety of new KOR-targeted drugs.

Literature Review
A growing body of literature supports the utility of dynorphin (2-17) in neuropharmacological research:

1. **Chavkin & Goldstein (1981, Proc Natl Acad Sci USA):** This seminal study characterized the binding of dynorphin peptides to opioid receptors, establishing the foundation for subsequent research on KOR-selective ligands.

2. **Vanderah et al. (1996, J Pharmacol Exp Ther):** Investigated the pronociceptive and analgesic actions of dynorphin (2-17) in rodent models, demonstrating its complex role in pain modulation.

3. **Simonin et al. (1998, J Biol Chem):** Explored the molecular pharmacology of KOR, highlighting the importance of dynorphin fragments in receptor activation and signaling.

4. **Hauser et al. (1999, Brain Res):** Examined the neurotoxic potential of dynorphin (2-17) in the hippocampus, providing insights into its role in neurodegeneration.

5. **Carlezon et al. (2009, Pharmacol Rev):** Reviewed the involvement of the dynorphin/KOR system in mood disorders, emphasizing the translational relevance of dynorphin (2-17) in preclinical studies.

6. **Nikolarakis et al. (1986, J Neurochem):** Demonstrated the regulatory effects of dynorphin peptides on the HPA axis, linking opioid signaling to stress physiology.

7. **Wee & Koob (2010, Pharmacol Ther):** Discussed the therapeutic potential and challenges of targeting KOR in addiction and mood disorders, referencing the use of dynorphin analogs in experimental paradigms.

Experimental Data and Results
Experimental studies employing dynorphin (2-17), amide, porcine, have yielded important findings regarding its pharmacological actions:

- **Receptor Binding and Efficacy:** In vitro assays demonstrate that dynorphin (2-17) binds with high affinity to KOR, eliciting robust G-protein activation and downstream signaling (Simonin et al., 1998, J Biol Chem). The amide modification enhances peptide stability, prolonging its bioactivity in biological systems.

- **Pain Modulation:** In rodent models, intrathecal administration of dynorphin (2-17) produces dose-dependent analgesia, which is reversed by selective KOR antagonists (Vanderah et al., 1996, J Pharmacol Exp Ther). Notably, at higher concentrations, the peptide can induce hyperalgesia, reflecting its dual modulatory capacity.

- **Neurotoxicity and Neuroprotection:** Hauser et al. (1999, Brain Res) reported that high concentrations of dynorphin (2-17) induce neuronal cell death in hippocampal cultures, mediated by non-opioid mechanisms such as NMDA receptor activation and oxidative stress. Conversely, physiological levels may confer neuroprotection under certain conditions.

- **Behavioral Effects:** Administration of dynorphin (2-17) in animal models results in behavioral changes consistent with KOR activation, including reduced locomotor activity, anhedonia, and stress-like responses (Carlezon et al., 2009, Pharmacol Rev). These effects are instrumental in modeling depression and addiction phenotypes.

- **Endocrine Effects:** Nikolarakis et al. (1986, J Neurochem) demonstrated that dynorphin (2-17) modulates corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion, implicating it in stress adaptation.

Usage Guidelines and Best Practices
For research applications, dynorphin (2-17), amide, porcine, should be handled and administered according to established protocols to ensure reproducibility and safety:

- **Preparation:** The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile, distilled water or physiological saline. Aliquots should be stored at -20°C to maintain stability.

- **Dosage and Administration:** Experimental dosages vary depending on the model system and research objective. In rodent studies, intrathecal or intracerebroventricular administration is common, with doses ranging from 0.1 to 10 nmol per animal (Vanderah et al., 1996, J Pharmacol Exp Ther). Dose-response studies are recommended to determine optimal concentrations.

- **Controls:** Use of appropriate controls Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199